Cumberland Pharmaceuticals announced yesterday its Caldolor injectable for treatment of pain and fever won FDA approval for sale in the U.S., following a priority review. For the moment, apparently the product has no peer. The Cumberland drug is a formulation of ibuprofen. In addition to a statement by CP CEO A. J. Kazimi, yesterday's press release included a quote from Vanderbilt University Assistant Vice Chancellor for Research Ken Holroyd (at left), who said the product is "welcomed." Vanderbilt partners with Cumberland in ownership of a local incubator, Cumberland Emerging Technologies. Holroyd serves on CET's board of directors. This week, Vanderbilt Vice Chancellor-Health Affairs Jeff Balser issued a new statement of Vanderbilt guidelines regarding averting conflicts of interest that might arise in relationships between University personnel and pharmaceutical companies, or other allies.
Friday, June 12, 2009
Cumberland Pharma's Caldolor gets FDA nod
Cumberland Pharmaceuticals announced yesterday its Caldolor injectable for treatment of pain and fever won FDA approval for sale in the U.S., following a priority review. For the moment, apparently the product has no peer. The Cumberland drug is a formulation of ibuprofen. In addition to a statement by CP CEO A. J. Kazimi, yesterday's press release included a quote from Vanderbilt University Assistant Vice Chancellor for Research Ken Holroyd (at left), who said the product is "welcomed." Vanderbilt partners with Cumberland in ownership of a local incubator, Cumberland Emerging Technologies. Holroyd serves on CET's board of directors. This week, Vanderbilt Vice Chancellor-Health Affairs Jeff Balser issued a new statement of Vanderbilt guidelines regarding averting conflicts of interest that might arise in relationships between University personnel and pharmaceutical companies, or other allies.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment